Format

Send to

Choose Destination
Int J Biol Sci. 2012;8(1):1-14. Epub 2011 Nov 5.

Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.

Author information

1
Department of Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou, China.

Abstract

Evodiamine has therapeutic potential against cancers. This study was designed to investigate whether combination therapy with gemcitabine and evodiamine enhanced antitumor efficacy in pancreatic cancer. In vitro application of the combination therapy triggered significantly higher frequency of pancreatic cancer cells apoptosis, inhibited the activities of PI3K, Akt, PKA, mTOR and PTEN, and decreased the activation of NF-κB and expression of NF-κB-regulated products. In vivo application of the combination therapy induced significant enhancement of tumor cell apoptosis, reductions in tumor volume, and inhibited activation of mTOR and PTEN. In conclusion, evodiamine can augment the therapeutic effect of gemcitabine in pancreatic cancer through direct or indirect negative regulation of the PI3K/Akt pathway.

KEYWORDS:

PTEN; apoptosis; evodiamine; gemcitabine; mTOR; pancreatic cancer SW1990 cells

PMID:
22211100
PMCID:
PMC3226028
DOI:
10.7150/ijbs.8.1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center